$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

$ssy Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-K Financial Statement

#000156459020044839 Filed on September 29, 2020

Income Statement

Concept	2020 Q3	2020	2019 Q2
Revenue	$10.42M	$47.81M	$10.90M
YoY Change	-10.56%	4.81%	-10.77%
Cost Of Revenue	$4.070M	$19.02M	$4.230M
YoY Change	-6.31%	0.43%	8.29%
Gross Profit	$6.352M	$28.79M	$6.669M
YoY Change	-13.08%	7.92%	-19.73%
Gross Profit Margin	60.95%	60.21%	61.19%
Selling, General & Admin	$5.426M	$24.30M	$6.107M
YoY Change	-10.9%	3.2%	-17.25%
% of Gross Profit	85.42%	84.41%	91.57%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$300.0K	$1.450M	$430.0K
YoY Change	-10.45%	-16.09%	-18.25%
% of Gross Profit	4.72%	5.04%	6.45%
Operating Expenses	$6.675M	$29.12M	$7.506M
YoY Change	-11.33%	0.89%	-20.08%
Operating Profit	-$323.0K	-$329.0K	-$837.0K
YoY Change	46.82%	-85.78%	-22.79%
Interest Expense	-$7.000K	-$29.00K	-$56.00K
YoY Change	-123.33%	-112.03%	-1.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$291.0K	-$290.0K	-$999.0K
YoY Change	103.5%	-86.04%	-13.36%
Income Tax	$0.00	$296.0K	$144.0K
% Of Pretax Income
Net Earnings	-$340.0K	-$1.140M	-$2.221M
YoY Change	30.27%	-35.01%	52.75%
Net Earnings / Revenue	-3.26%	-2.38%	-20.38%
Basic Earnings Per Share		-$0.16
Diluted Earnings Per Share	-$49.28K	-$0.16	-$317.9K
COMMON SHARES
Basic Shares Outstanding	6.899M	6.957M	6.987M
Diluted Shares Outstanding		6.957M

Balance Sheet

Concept	2020 Q3	2020	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.40M	$11.18M	$7.742M
YoY Change	48.67%	44.46%	124.02%
Cash & Equivalents	$11.40M	$11.18M	$7.742M
Short-Term Investments
Other Short-Term Assets	$2.455M	$2.558M	$2.185M
YoY Change	8.1%	17.07%	-25.6%
Inventory	$1.965M	$1.866M	$2.016M
Prepaid Expenses
Receivables	$4.195M	$4.315M	$4.715M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.02M	$19.92M	$16.66M
YoY Change	17.3%	19.6%	27.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.495M	$6.294M	$5.243M
YoY Change	25.17%	20.05%	-11.08%
Goodwill
YoY Change
Intangibles			$1.353M
YoY Change			-7.96%
Long-Term Investments
YoY Change
Other Assets	$485.0K	$500.0K	$1.165M
YoY Change	-36.35%	-50.59%	31.64%
Total Long-Term Assets	$8.227M	$8.048M	$7.761M
YoY Change	42.9%	3.7%	-40.6%
TOTAL ASSETS
Total Short-Term Assets	$20.02M	$19.92M	$16.66M
Total Long-Term Assets	$8.227M	$8.048M	$7.761M
Total Assets	$28.25M	$27.97M	$24.42M
YoY Change	23.76%	14.55%	-6.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.614M	$872.0K	$1.564M
YoY Change	3.79%	-44.25%	26.23%
Accrued Expenses	$4.465M	$4.611M	$4.010M
YoY Change	-9.21%	14.99%	1282.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.402M	$1.401M	$2.836M
YoY Change	-49.42%	-50.6%	1012.16%
Total Short-Term Liabilities	$12.09M	$11.42M	$8.410M
YoY Change	30.75%	35.74%	73.37%
LONG-TERM LIABILITIES
Long-Term Debt	$1.948M	$1.957M	$127.0K
YoY Change	1593.91%	1440.94%	-95.47%
Other Long-Term Liabilities	$173.0K	$855.0K	$134.0K
YoY Change	10.19%	1.91%	-60.59%
Total Long-Term Liabilities	$2.754M	$2.812M	$966.0K
YoY Change	56.83%	191.1%	-76.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.09M	$11.42M	$8.410M
Total Long-Term Liabilities	$2.754M	$2.812M	$966.0K
Total Liabilities	$14.84M	$14.23M	$9.376M
YoY Change	34.92%	51.75%	4.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$422.0K		$1.058M
YoY Change	-152.95%		-61.43%
Common Stock	$14.16M		$14.24M
YoY Change	-0.71%		-2.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.40M	$13.74M	$15.04M
YoY Change
Total Liabilities & Shareholders Equity	$28.25M	$27.97M	$24.42M
YoY Change	9.43%	14.55%	-6.71%

Cashflow Statement

Concept	2020 Q3	2020	2019 Q2
OPERATING ACTIVITIES
Net Income	-$340.0K	-$1.140M	-$2.221M
YoY Change	30.27%	-35.01%	52.75%
Depreciation, Depletion And Amortization	$300.0K	$1.450M	$430.0K
YoY Change	-10.45%	-16.09%	-18.25%
Cash From Operating Activities	$814.0K	$3.969M	-$910.0K
YoY Change	-956.84%	-378.14%	-312.12%
INVESTING ACTIVITIES
Capital Expenditures	$595.0K	$1.185M	-$405.0K
YoY Change	137.05%	-6.84%	12.81%
Acquisitions
YoY Change
Other Investing Activities	$8.000K	$559.0K	$0.00
YoY Change	-97.75%	-92.87%	-100.0%
Cash From Investing Activities	-$587.0K	-$626.0K	-$405.0K
YoY Change	-664.42%	-109.79%	17.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$102.0K
YoY Change		-73.37%
Debt Paid & Issued, Net	$8.000K	$3.033M
YoY Change	-90.12%	924.66%
Cash From Financing Activities	-8.000K	99.00K	-103.0K
YoY Change	-90.12%	-114.58%	-38.69%
NET CHANGE
Cash From Operating Activities	814.0K	3.969M	-910.0K
Cash From Investing Activities	-587.0K	-626.0K	-405.0K
Cash From Financing Activities	-8.000K	99.00K	-103.0K
Net Change In Cash	219.0K	3.442M	-1.418M
YoY Change	-404.17%	-19.69%	1568.24%
FREE CASH FLOW
Cash From Operating Activities	$814.0K	$3.969M	-$910.0K
Capital Expenditures	$595.0K	$1.185M	-$405.0K
Free Cash Flow	$219.0K	$2.784M	-$505.0K
YoY Change	-163.29%	-203.15%	-164.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Local Phone Number LocalPhoneNumber	933-7000
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11184000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7742000
CY2019Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4715000
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Circle 75 Parkway
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 690
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30339
CY2020	dei	City Area Code CityAreaCode	770
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6899321
CY2019Q4	dei	Entity Public Float EntityPublicFloat	4383480
CY2020	dei	Entity File Number EntityFileNumber	1-12607
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	OH
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-0621189
CY2020Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4315000
CY2019	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	455000
CY2019	us-gaap	Supplies Expense SuppliesExpense	1241000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3969000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-2314000
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	609000
CY2020	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3366000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1486000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-329000
CY2020Q2	us-gaap	Inventory Net InventoryNet	1866000
CY2019Q2	us-gaap	Inventory Net InventoryNet	2016000
CY2020Q2	us-gaap	Land Land	582000
CY2019Q2	us-gaap	Land Land	273000
CY2020Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	5363000
CY2019Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	5429000
CY2020Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13804000
CY2019Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13818000
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19749000
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19520000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14425000
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14277000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5324000
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5243000
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1254000
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1353000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	970000
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	500000
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1165000
CY2020Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2724000
CY2019Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2518000
CY2020Q2	us-gaap	Assets Assets	27971000
CY2019Q2	us-gaap	Assets Assets	24419000
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	872000
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1564000
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1401000
CY2019Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2836000
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1969000
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1960000
CY2020Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1411000
CY2019Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	843000
CY2020Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	4532000
CY2019Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	0
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	365000
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	866000
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1207000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11416000
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8410000
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1957000
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	127000
CY2020Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	104000
CY2019Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	705000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	607000
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	144000
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	134000
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2812000
CY2019Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	966000
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	-7000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-76000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1226000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1830000
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
CY2020	ssy	Federal Stimulus Pandemic Relief Funds FederalStimulusPandemicReliefFunds	54000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-290000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2078000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	296000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-82000
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-586000
CY2019	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1996000
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.28
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.08
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-86000
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.28
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.08
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.03
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.08
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6957000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7149000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6957000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7149000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9000
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	3450000
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	3493000
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10714000
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10745000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82000
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1058000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-339000
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-253000
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13743000
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15043000
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27971000
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24419000
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2020Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2019Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2020Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2019Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6899000
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6987000
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6899000
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6987000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47813000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45618000
CY2020	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19563000
CY2019	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19191000
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	601000
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	129000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1450000
CY2020	ssy	Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss	0
CY2019	ssy	Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss	68000
CY2019	ssy	Federal Stimulus Pandemic Relief Funds FederalStimulusPandemicReliefFunds	0
CY2020	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	22000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-29000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-241000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-178000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201802Member
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1000
CY2019	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	383000
CY2020	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	-86000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28000
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	102000
CY2020	us-gaap	Profit Loss ProfitLoss	-1140000
CY2019	us-gaap	Profit Loss ProfitLoss	-1754000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1450000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1728000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	28000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	192000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	455000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-400000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-108000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-150000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	162000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1049000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1624000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	588000
CY2020	ssy	Increase Decrease In Deferred Relief Funds IncreaseDecreaseInDeferredReliefFunds	4532000
CY2019	ssy	Increase Decrease In Deferred Relief Funds IncreaseDecreaseInDeferredReliefFunds	0
CY2020	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	569000
CY2019	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	602000
CY2020	ssy	Increase Decrease In Third Party Payor Settlements IncreaseDecreaseInThirdPartyPayorSettlements	214000
CY2019	ssy	Increase Decrease In Third Party Payor Settlements IncreaseDecreaseInThirdPartyPayorSettlements	218000
CY2020	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0
CY2019	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-907000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1427000
CY2020	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6899000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	559000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	937000
CY2020	ssy	Payments To Acquire Property Plant And Equipment Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations	1185000
CY2019	ssy	Payments To Acquire Property Plant And Equipment Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations	1272000
CY2020	ssy	Payments To Acquire Property Plant And Equipment Discontinuing Operations PaymentsToAcquirePropertyPlantAndEquipmentDiscontinuingOperations	0
CY2019	ssy	Payments To Acquire Property Plant And Equipment Discontinuing Operations PaymentsToAcquirePropertyPlantAndEquipmentDiscontinuingOperations	172000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-626000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6392000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	102000
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	383000
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3234000
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3033000
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	296000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	99000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-679000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3442000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4286000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7742000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3456000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11184000
CY2020	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0
CY2019	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	176000
CY2020	us-gaap	Transfer To Other Real Estate TransferToOtherRealEstate	371000
CY2019	us-gaap	Transfer To Other Real Estate TransferToOtherRealEstate	0
CY2020	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	1498000
CY2019	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	0
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-349000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	222000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. BUSINESS OPERATIONS</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink Health Systems, Inc., through subsidiaries (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”), owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Services</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A subsidiary which owns and operates Trace Regional Hospital and Floy Dyer Nursing Home (“Trace”), an 84 licensed-bed acute care hospital, located in Houston, Mississippi, which includes an 18-bed geriatric psychology unit (“GPU”), and a 66-bed nursing home. This facility focuses primarily on senior healthcare services.</font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">A <font style="font-family:Times New Roman;">subsidiary, SunLink Health Systems Technology (“SHST Technology”), which provides information technology (“IT”) to outside customers and to SunLink subsidiaries. </font><font style="font-family:Calibri;font-size:11pt;"> </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">A <font style="font-family:Times New Roman;">subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi</font>. </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A subsidiary which owns approximately 25 acres of unimproved land in Ellijay, Georgia.</font> </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pharmacy</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy segment, which is composed of four operational areas:</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in rural markets at two locations in Louisiana</font>. </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.</font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes. </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:9.07%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</font></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property. The operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#212529;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">COVID-19 Pandemic and CARES Act Funding</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (“COVID-19”) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance are very recent, rapidly changing and at times, unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and have been placed on leave or in quarantine. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Healthcare businesses, we have experienced material reductions in demand due to the COVID-19 outbreak. There appears to be minimal current demand for nursing home admissions, and clinic visits and hospital services have substantially decreased as well in part due to the abrupt retirement of one physician and reduced capacity of other physicians and providers, all as a result of the effects of the pandemic. The availability and cost of medical supplies have adversely affected our Healthcare businesses, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials. We continue to monitor supplies and seek additional sources of many supply items. A reduction of the availability of qualified employees has also occurred and despite good faith efforts to do, they have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced negative sales trends, increased costs and reduced staff.  Retail Pharmacy and DME locations are operating with curbside or drive-through services only and many of our primary physician referral sources have been closed or are operating at substantially reduced capacity.  Until these referral sources are open and fully-staffed, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Demand for our Institutional Pharmacy services has been less affected to date. Nursing homes and other customers of such Institutional Pharmacy services are currently being adversely affected by the spreading of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand.  Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products. We believe the effect of the COVID–19 pandemic and public and governmental responses to it negatively affected our third and fourth fiscal quarters results.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;"> </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of fiscal 2020, our Healthcare and Pharmacy segments received approximately $4,586 in general and targeted Provider Relief Fund (“PRF”) distributions and $3,234 in Paycheck Protection Programs (“PPP”) loans, administered by the , SBA, both provided for under the CARES Act for a total of $7,820 of such funding. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distributions from the PRF are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for healthcare-related expenses or “Lost Revenues” (as defined by HHS) attributable to COVID-19. Such funds under the PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds will be met. Based on an analysis of the compliance and reporting requirements of the PRF and the impact of the pandemic on our operating results through the end of our fiscal year ended June 30, 2020, we recognized $54 of income related to PRF and these funds are recorded under the caption “Federal stimulus pandemic relief funds” in other income (expense) in our consolidated statement of operations. The unrecognized amount of the PRF are recorded under the caption “Deferred income- CARES Act” in our consolidated balance sheets. We will continue to monitor compliance under the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the distributions received may be impacted.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forgiveness of PPP loans may be available if the loans are used to pay wages, rent, utilities and interest on certain debt during the eight-week period following receipt of the loan proceeds subject to Federally-established terms and conditions.  During July 2020, the allowable period for the use of loan proceeds was amended to allow for a 24-week period in which to utilize PPP loan  proceeds. The borrowing subsidiaries must apply for loan forgiveness with the lending bank within ten months after the end of the allowable period. The forgiveness applications are to be reviewed by both the lender and the Small Business Administration (“SBA”) and a loan forgiveness amount, if any, will be determined. There can be no assurance, however, that any of the PPP loans to us will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a 1% annual interest rate. The two-year loan repayment begins two months after the loan forgiveness amount is determined by SBA. The Company had not applied for forgiveness of any of its PPP loans and recorded no income relating to the PPP loans at June 30, 2020.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited.  The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; and existing and potential government assistance that may be provided. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that existing funds, cash generated from operations and additional sources of and access to financing from COVID-19 related government loans and grants will likely be adequate to satisfy our needs for working capital and capital expenditures in the near term. However, if the COVID-19 pandemic continues for an extended period, we expect to experience significant losses and additional financial assistance will likely be required. </p>
CY2020	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. ECONOMIC DAMAGES</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and a payment of approximately $22<font style="font-family:Calibri;font-size:11pt;"> </font>(net of costs and attorneys’ fees) for the year ended June 30, 2019 was received. The net settlement was recognized as a gain in the results for the year ended June 30, 2019.</p>
CY2020	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	9000
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management Estimates<font style="font-weight:normal;font-style:normal;"> —The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates made by management involve reserves for adjustments to net patient service revenues, evaluation of the recoverability of assets, including accounts receivable and intangible assets, and the assessment of litigation and contingencies, including income taxes and related tax asset valuation allowances, all as discussed in more detail in the remainder of these notes to the consolidated financial statements. Actual results could differ materially from these estimates.</font></p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk<font style="font-weight:normal;font-style:normal;"> —SunLink’s Healthcare Services segment subsidiaries grant unsecured credit to their patients, most of who reside in the service area of the subsidiaries’ facilities and are insured under third-party agreements. Medicare and Medicaid patient accounts represent SunLink’s only significant concentrations of credit risk. For SunLink’s Healthcare Services segment, Medicare net revenues were approximately 52% and 49% of net revenues for the years ended June 30, 2020 and 2019, respectively. For SunLink’s Healthcare Services segment, Medicaid was approximately 32% and 33% net revenues for the years ended June 30, 2020 and 2019, respectively. For SunLink’s Healthcare Services segment, Medicare receivables were approximately 45% and 42% of receivables—net at June 30, 2020 and 2019, respectively, while Medicaid receivables were approximately 21% and 26% of receivables—net at June 30, 2020 and 2019, respectively.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink’s Pharmacy segment subsidiary grants unsecured credit to individual customers and institutional customers. Individual customers primarily are insured under third-party agreements, including Medicare and Medicaid, while the institutional customers are granted credit according to their determined credit risk. Medicare receivables were approximately 23% and 17% of the Pharmacy segment’s receivables at June 30, 2020 and 2019, respectively, while Medicaid receivables were approximately 23% and 17% of the Pharmacy segment receivable at June 30, 2020 and 2019, respectively. Approximately 54% and 66% of the Pharmacy’s net receivables at June 30, 2020 and 2019, respectively, were private insurance and institutional customers’ receivables. Net revenues for the Pharmacy segment for the fiscal year ended June 30, 2020 and 2019 were approximately 37% and 35% Medicare, respectively, and approximately 28% and 29% Medicaid, respectively.</p>
CY2020	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	139000
CY2019	ssy	Disposal Group Including Discontinued Operation Revenue Net Of Expenses DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses	4993000
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-554000
CY2019	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1812000
CY2020	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0
CY2019	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	2136000
CY2020	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2019	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	82000
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020Q2	us-gaap	Cash Cash	11178000
CY2020Q2	ssy	Cash Deposits In Excess Of Federally Insured Limits CashDepositsInExcessOfFederallyInsuredLimits	10384000
CY2020	ssy	Overnight Repurchase Agreements Collateralized By Government Backed Securities OvernightRepurchaseAgreementsCollateralizedByGovernmentBackedSecurities	1.02
CY2020	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	Depreciation is recognized over the estimated useful lives of the assets, which range from 3 to 45 years, on a straight-line basis.
CY2020	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	Estimated useful lives of the assets, which range from 3 to 45 years, on a straight-line basis.
CY2020	us-gaap	Depreciation Depreciation	1350000
CY2019	us-gaap	Depreciation Depreciation	1369000
CY2020	ssy	Disposal Group Including Discontinued Operation Revenue Net Of Expenses DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses	37000
CY2019	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	-15000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	593000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	5000
CY2020	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	3000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	601000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	36000
CY2020	ssy	Finance Lease Cost FinanceLeaseCost	45000
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentNet
CY2020Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	43000
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	34000
CY2020Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:LongTermDebtCurrent
CY2020Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	90000
CY2020Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:LongTermDebtNoncurrent
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	593000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	32000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1498000
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2020Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M28D
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0654
CY2020Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0549
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	406000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1904000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	480000
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2836000
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1957000
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	127000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1401000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	275000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	106000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	101000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	74000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1077000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	105000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	972000
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	42000
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	42000
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	42000
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	13000
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2020Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2020Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	139000
CY2020Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	15000
CY2020Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	124000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	99000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	117000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	26000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	26000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	22000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	0
CY2020Q2	ssy	Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafterFive	0
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	74000
CY2020Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	124000
CY2019Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	159000
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	3358000
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	3158000
CY2020Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0
CY2019Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	195000
CY2020Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1401000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	39000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	14000
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0
CY2020Q2	ssy	Long Term Debt Maturities Repayments Of Principal In Year Six And After Year Six LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSixAndAfterYearSix	0
CY2020Q2	us-gaap	Long Term Debt LongTermDebt	3358000
CY2020Q2	ssy	Long Term Debt Contractual Commitments For Interest In Next Twelve Months LongTermDebtContractualCommitmentsForInterestInNextTwelveMonths	45000
CY2020Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Two LongTermDebtContractualCommitmentsForInterestInYearTwo	33000
CY2020Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Three LongTermDebtContractualCommitmentsForInterestInYearThree	2000
CY2020Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Four LongTermDebtContractualCommitmentsForInterestInYearFour	0
CY2020Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Five LongTermDebtContractualCommitmentsForInterestInYearFive	0
CY2020Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Six And After Year Six LongTermDebtContractualCommitmentsForInterestInYearSixAndAfterYearSix	0
CY2020Q2	ssy	Long Term Debt Contractual Commitments LongTermDebtContractualCommitments	80000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	651000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	56000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	595000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	165000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	595000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	480000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.52
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1407000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	603000
CY2020	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	175000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.46
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.53
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.38
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.01
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.35
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.52
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.35
CY2020	ssy	Share Based Compensation Arrangement By Share Based Payments Award Options Grants In Period Range Of Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodRangeOfExercisePrice	1.38
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	132000
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	74000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	132000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	74000
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2020	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	87534
CY2020	ssy	Share Repurchase Average Price Per Share Paid ShareRepurchaseAveragePricePerSharePaid	1.15
CY2019	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	359959
CY2019	ssy	Share Repurchase Average Price Per Share Paid ShareRepurchaseAveragePricePerSharePaid	1.03
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-177000
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-76000
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-253000
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-86000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-339000
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-177000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	296000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-82000
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6078000
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6766000
CY2020Q2	ssy	Deferred Tax Assets Depreciation Expense DeferredTaxAssetsDepreciationExpense	-86000
CY2019Q2	ssy	Deferred Tax Assets Depreciation Expense DeferredTaxAssetsDepreciationExpense	46000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	131000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	125000
CY2020Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	585000
CY2019Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	877000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions	165000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions	141000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	109000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	67000
CY2020Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8389000
CY2019Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8625000
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8389000
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8625000
CY2020Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-61000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-436000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-369000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	378000
CY2019	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	-45000
CY2020	ssy	Income Tax Reconciliation Permanent Differences Under Cares Act IncomeTaxReconciliationPermanentDifferencesUnderCARESAct	582000
CY2019	ssy	Income Tax Reconciliation Permanent Differences Under Cares Act IncomeTaxReconciliationPermanentDifferencesUnderCARESAct	0
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-34000
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	32000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-11000
CY2020	ssy	Number Of Taxing Authorities NumberOfTaxingAuthorities	2
CY2020	ssy	Percentage Of Net Operating Losses Limitation Under Tax Cuts And Jobs Act PercentageOfNetOperatingLossesLimitationUnderTaxCutsAndJobsAct	0.80
CY2020Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	359000
CY2020	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	469000
CY2019	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	384000
CY2020Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	923000
CY2020	ssy	Taxable Income Under Cares Act TaxableIncomeUnderCARESAct	7303000
CY2020	ssy	Income Taxes Alternative Minimum Tax Credit Received Cares Act IncomeTaxesAlternativeMinimumTaxCreditReceivedCARESAct	305000
CY2020Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17500000
CY2020	ssy	Net Operating Loss Carry Forwards Expire Period NetOperatingLossCarryForwardsExpirePeriod	2023 through fiscal 2038
CY2020Q2	ssy	Plans Assets Invested In Cash And Short Term Investments PlansAssetsInvestedInCashAndShortTermInvestments	0.47
CY2020Q2	ssy	Plans Assets Invested In Equity Investments PlansAssetsInvestedInEquityInvestments	0.36
CY2020Q2	ssy	Plans Assets Invested In Fixed Income Investments PlansAssetsInvestedInFixedIncomeInvestments	0.17
CY2020	ssy	Expected Return On Investment ExpectedReturnOnInvestment	0.04
CY2020Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	52000
CY2020Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	50000
CY2020Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	61000
CY2020Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	60000
CY2020Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	174000
CY2020Q2	ssy	Plan Expected To Pay In Pension Benefits Through Three Years PlanExpectedToPayInPensionBenefitsThroughThreeYears	363000
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	132000
CY2019	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	107000
CY2020Q2	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	100000
CY2020	ssy	Age Of Participants To Take Monthly Pension Benefits One AgeOfParticipantsToTakeMonthlyPensionBenefitsOne	P65Y
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0350
CY2019	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0410
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0400
CY2019	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0400
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0000
CY2019	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0000
CY2019Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1390000
CY2018Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1420000
CY2020	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	47000
CY2019	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	56000
CY2020	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-168000
CY2019	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-90000
CY2020	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	31000
CY2019	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	176000
CY2020Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1574000
CY2019Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	827000
CY2018Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	895000
CY2020	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-5000
CY2019	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	1000
CY2020	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	31000
CY2019	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	176000
CY2020Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-651000
CY2019Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-563000
CY2020Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-182000
CY2019Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-179000
CY2020Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-182000
CY2019Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-179000
CY2020Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	469000
CY2019Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	384000
CY2020Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-651000
CY2019Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-563000
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2019	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2020	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	137000
CY2019	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	85000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1185000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1272000
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31000

Files In Submission

Name	View Source	Status
0001564590-20-044839-index-headers.html	Edgar Link	pending
0001564590-20-044839-index.html	Edgar Link	pending
0001564590-20-044839.txt	Edgar Link	pending
0001564590-20-044839-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g3wlcg0tll24000001.jpg	Edgar Link	pending
gcrrhl1svgrs000001.jpg	Edgar Link	pending
ghhrsi0on2ux000001.jpg	Edgar Link	pending
gil2igmfieem000001.jpg	Edgar Link	pending
gmlrhu5ekcnn000001.jpg	Edgar Link	pending
gwcve0lrjs1l000001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ssy-10k_20200630.htm	Edgar Link	pending
ssy-20200630.xml	Edgar Link	completed
ssy-20200630.xsd	Edgar Link	pending
ssy-20200630_cal.xml	Edgar Link	unprocessable
ssy-20200630_def.xml	Edgar Link	unprocessable
ssy-20200630_lab.xml	Edgar Link	unprocessable
ssy-20200630_pre.xml	Edgar Link	unprocessable
ssy-ex1010_713.htm	Edgar Link	pending
ssy-ex1011_712.htm	Edgar Link	pending
ssy-ex1012_711.htm	Edgar Link	pending
ssy-ex107_716.htm	Edgar Link	pending
ssy-ex108_715.htm	Edgar Link	pending
ssy-ex109_714.htm	Edgar Link	pending
ssy-ex211_8.htm	Edgar Link	pending
ssy-ex231_11.htm	Edgar Link	pending
ssy-ex311_6.htm	Edgar Link	pending
ssy-ex312_12.htm	Edgar Link	pending
ssy-ex321_10.htm	Edgar Link	pending
ssy-ex322_7.htm	Edgar Link	pending
ssy-ex3i_1192.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

2020 Q3 Form 10-K Financial Statement

#000156459020044839 Filed on September 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY SUNLINK HEALTH SYSTEMS INC Stock $ssy

2020 Q3 Form 10-K Financial Statement

#000156459020044839 Filed on September 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy